MedTrace Logo

A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

NCT02237157 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-05-07

Study results available
· View outcomes & findings →

Summary

A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.

Conditions

Interventions

DRUG

Gemcitabine, local delivery

Intra-arterial targeted drug delivery

Sponsors & Collaborators

  • RenovoRx

    lead INDUSTRY

Principal Investigators

  • Jiali Li, MD · El Camino Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237157 on ClinicalTrials.gov